In the News
Press Releases
Alzheon Announces Scientific Presentation at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference Taking Place on December 4-7 in San Diego, USA
New Data Shows Significantly Higher Rate of Cortical Thickness Loss in Early Alzheimer’s Patients with APOE4/4 Genotype Cortical Thickness May Be a Useful Biomarker in Future [...]
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course Publication Outlines Therapeutic Characteristics [...]
Alzheon Presents Data on the Discovery of 3-SPA, an Endogenous Substance in the Human Brain, at the Alzheimer’s Association International Conference
3-SPA, also a Product of ALZ-801, Prevents Formation of Toxic Beta Amyloid Oligomers, the Key Driver of Alzheimer’s Disease FRAMINGHAM, Mass., July 14, 2019 – Alzheon, Inc., a [...]
Alzheon to Make Presentations at Upcoming Industry Conferences
Keynote Lectures at Neurotech, China Focus and Alzheimer’s Solutions Conference FRAMINGHAM, Mass., May 13, 2019 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio [...]
Alzheon to Make Presentations at Upcoming Industry Conferences
Keynote at World CNS Summit and Company Presentation at Noble Healthcare Conference FRAMINGHAM, Mass., January 21, 2019 – Alzheon, Inc., a clinical-stage biopharmaceutical company developing a [...]
Alzheon to Present Clinical Data at 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Alzheon to Present Clinical Data at 11th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference FRAMINGHAM, Mass., October 24, 2018 – Alzheon, Inc., (Alzheon) a clinical [...]